Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Gene | HRAS |
Variant | G12C |
Impact List | missense |
Protein Effect | loss of function |
Gene Variant Descriptions | HRAS G12C does not lie within any known functional domains of the Hras protein (UniProt.org). G12C results in decreased Hras GTPase activity, loss of sensitivity to GTPase-activating proteins, thus leads to transformation of cells in culture (PMID: 24224811, PMID: 6092966). |
Associated Drug Resistance | |
Category Variants Paths |
HRAS mutant HRAS act mut HRAS G12C HRAS mutant HRAS G12X HRAS G12C |
Transcript | NM_005343.4 |
gDNA | chr11:g.534289C>A |
cDNA | c.34G>T |
Protein | p.G12C |
Source Database | RefSeq |
Genome Build | GRCh38/hg38 |
Transcript | gDNA | cDNA | Protein | Source Database | Genome Build |
---|---|---|---|---|---|
NM_176795.4 | chr11:g.534289C>A | c.34G>T | p.G12C | RefSeq | GRCh38/hg38 |
NM_005343 | chr11:g.534289C>A | c.34G>T | p.G12C | RefSeq | GRCh38/hg38 |
NM_001130442 | chr11:g.534289C>A | c.34G>T | p.G12C | RefSeq | GRCh38/hg38 |
NM_176795 | chr11:g.534289C>A | c.34G>T | p.G12C | RefSeq | GRCh38/hg38 |
NM_005343.3 | chr11:g.534289C>A | c.34G>T | p.G12C | RefSeq | GRCh38/hg38 |
NM_001130442.3 | chr11:g.534289C>A | c.34G>T | p.G12C | RefSeq | GRCh38/hg38 |
NM_176795.5 | chr11:g.534289C>A | c.34G>T | p.G12C | RefSeq | GRCh38/hg38 |
NM_005343.4 | chr11:g.534289C>A | c.34G>T | p.G12C | RefSeq | GRCh38/hg38 |
NM_001130442.2 | chr11:g.534289C>A | c.34G>T | p.G12C | RefSeq | GRCh38/hg38 |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
HRAS G12C | head and neck squamous cell carcinoma | predicted - sensitive | Tipifarnib | Preclinical - Cell line xenograft | Actionable | In a preclinical study, a head and neck squamous cell carcinoma cell line xenograft model harboring HRAS G12C was sensitive to treatment with Zarnestra (tipifarnib), demonstrating inhibition of tumor growth and vessel formation, increased apoptotic activity, and decreased cell proliferation (PMID: 32727882). | 32727882 |